Alembic Pharma Releases FY26 Business Responsibility & Sustainability Report
Alembic Pharmaceuticals Ltd. has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, which includes a Reasonable Assurance Report from Bureau Veritas (India) Private Ltd., details the company's performance across environmental, social, and governance (ESG) parameters. Key disclosures cover corporate identity, business activities contributing 100% to turnover in pharmaceutical manufacturing, operational locations (12 national plants, 3 international offices), and market reach across 19 national states and 74 countries. The report also highlights employee demographics, with 16,324 permanent employees and 3,825 workers, and notes a significant export contribution of 57% to total turnover.
Key Highlights
- Alembic Pharma filed its FY26 Business Responsibility and Sustainability Report.
- Report includes Reasonable Assurance from Bureau Veritas (India) Private Ltd.
- Company's core business is pharmaceutical manufacturing (100% turnover).
- Exports constitute 57% of the company's total turnover.
- Disclosures cover ESG parameters for the standalone entity.
Price Impact
More from APLLTD
More in ESG